Cargando…
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV)’s impact on work loss remains poorly described. We evaluated associations between the duration of CINV episodes, CINV-related work loss (CINV-WL), and CINV-related activity impairment (CINV-AI) in patients with breast cancer receiving highly e...
Autores principales: | Schwartzberg, Lee, Navari, Rudolph M., Ruddy, Kathryn J., LeBlanc, Thomas W., Clark-Snow, Rebecca, Wickham, Rita, Kloth, Dwight, Binder, Gary, Bailey, William L., Turini, Marco, Potluri, Ravi, Liu, Xing, Papademetriou, Eros, Roeland, Eric J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600031/ https://www.ncbi.nlm.nih.gov/pubmed/37878086 http://dx.doi.org/10.1007/s00520-023-08119-1 |
Ejemplares similares
-
Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles
por: Navari, Rudolph, et al.
Publicado: (2022) -
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
por: Schwartzberg, Lee, et al.
Publicado: (2019) -
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014) -
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018) -
Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)